News

Atara Biotherapeutics has received a setback in its efforts to bring EBVALLO™ (tabelecleucel) to patients with Epstein-Barr virus–positive post-transplant lymphoproliferative disease…
Read More...

AbbVie has announced a voluntary agreement with the Trump administration aimed at expanding access and affordability of medicines for Americans while reinforcing the company’s long-term…
Read More...

AbbVie and RemeGen have entered into an exclusive global licensing agreement aimed at advancing RC148, a novel investigational bispecific antibody targeting both Programmed Cell Death-1…
Read More...

AbbVie and West Pharmaceutical Services have announced a definitive agreement under which AbbVie will acquire a device manufacturing facility and associated intellectual property from…
Read More...

Fortress Biotech, Inc. and its majority-owned subsidiary Cyprium Therapeutics have received a major regulatory milestone with the U.S. Food and Drug Administration’s approval of ZYCUBO®…
Read More...

BD (Becton, Dickinson and Company), a global leader in medical technology, has announced a $110 million investment to expand its production of prefillable syringes in the United States,…
Read More...

Solid Biosciences Inc., a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has reached two important milestones in the…
Read More...

Synaffix B.V., a Lonza company, and Sidewinder Therapeutics have entered into a multi-target licensing agreement aimed at developing first-in-class bispecific antibody-drug conjugate…
Read More...

Alessa Therapeutics has received Fast Track designation from the U.S. Food and Drug Administration for Enolen®, its lead investigational therapy for the treatment of low- to…
Read More...

Cellenkos Inc., a clinical-stage biotechnology company developing off-the-shelf regulatory T cell (Treg) therapies, has received Orphan Drug Designation from the U.S. Food and Drug…
Read More...

Santhera Pharmaceuticals has signed an exclusive licensing agreement with Nxera Pharma UK to develop, manufacture, and commercialize AGAMREE® (vamorolone) for the treatment of Duchenne…
Read More...

Eli Lilly and Company has reported positive topline results from its novel TOGETHER-PsA Phase 3b trial, demonstrating that the concomitant use of Taltz (ixekizumab) and Zepbound…
Read More...

Amgen has announced the acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom, in a deal valued at up to $840 million. The…
Read More...

Octapharma USA has received approval from the U.S. Food and Drug Administration for a new 2-gram presentation of Fibryga®, a human plasma-derived fibrinogen concentrate, expanding…
Read More...

GSK plc has reported positive results from two pivotal phase III clinical trials evaluating bepirovirsen, an investigational antisense oligonucleotide therapy for chronic hepatitis B…
Read More...

Takeda Pharmaceutical Company has entered into a global collaboration and license agreement with Halozyme Therapeutics to use Halozyme’s proprietary ENHANZE® drug delivery technology…
Read More...

Eli Lilly and Company has agreed to acquire Ventyx Biosciences in an all-cash transaction valued at approximately $1.2 billion, strengthening Lilly’s pipeline in inflammation-driven…
Read More...

Day One Biopharmaceuticals has completed its acquisition of Mersana Therapeutics, marking a significant expansion of its oncology pipeline and reinforcing its strategy to advance…
Read More...

Protara Therapeutics, Inc., a clinical-stage biotechnology company focused on cancer and rare diseases, has received multiple regulatory boosts from the U.S. Food and Drug…
Read More...

China’s drug regulator has expanded treatment options for patients with rare, genetically driven cancers by approving Zai Lab Limited’s AUGTYRO™ (repotrectinib) for adult patients with…
Read More...